Estimating Cost Savings from Early Cancer Diagnosis

Estimating Cost Savings from Early Cancer Diagnosis

We estimate treatment cost-savings from early cancer diagnosis. For breast, lung, prostate and colorectal cancers and melanoma, which account for more than 50% of new incidences projected in 2017, we combine published cancer treatment cost estimates by stage with incidence rates by stage at diagnosi...

Full description

Bibliographic Details
Main Authors: Zura Kakushadze, Rakesh Raghubanshi, Willie Yu
Format: Article
Language:English
Published: MDPI AG 2017-09-01
Series:Data
Subjects:
cancer
costs
incidence
stage
early diagnosis
treatment
data
Online Access:https://www.mdpi.com/2306-5729/2/3/30
id doaj-415a9a4d451146b2946979e6661508e2
record_format Article
spelling doaj-415a9a4d451146b2946979e6661508e22020-11-24T21:54:11ZengMDPI AGData2306-57292017-09-01233010.3390/data2030030data2030030Estimating Cost Savings from Early Cancer DiagnosisZura Kakushadze0Rakesh Raghubanshi1Willie Yu2Quantigic<sup>®</sup> Solutions LLC, 1127 High Ridge Road, #135, Stamford, CT 06905, USATwo29 Consulting LLC, 46 Sewell Avenue, Piscataway, NJ 08854, USACentre for Computational Biology, Duke-NUS Medical School, 8 College Road, Singapore 169857, SingaporeWe estimate treatment cost-savings from early cancer diagnosis. For breast, lung, prostate and colorectal cancers and melanoma, which account for more than 50% of new incidences projected in 2017, we combine published cancer treatment cost estimates by stage with incidence rates by stage at diagnosis. We extrapolate to other cancer sites by using estimated national expenditures and incidence rates. A rough estimate for the U.S. national annual treatment cost-savings from early cancer diagnosis is in 11 digits. Using this estimate and cost-neutrality, we also estimate a rough upper bound on the cost of a routine early cancer screening test.https://www.mdpi.com/2306-5729/2/3/30cancercostsincidencestageearly diagnosistreatmentdata
collection DOAJ
language English
format Article
sources DOAJ
author Zura Kakushadze
Rakesh Raghubanshi
Willie Yu
spellingShingle Zura Kakushadze
Rakesh Raghubanshi
Willie Yu
Estimating Cost Savings from Early Cancer Diagnosis
Data
cancer
costs
incidence
stage
early diagnosis
treatment
data
author_facet Zura Kakushadze
Rakesh Raghubanshi
Willie Yu
author_sort Zura Kakushadze
title Estimating Cost Savings from Early Cancer Diagnosis
title_short Estimating Cost Savings from Early Cancer Diagnosis
title_full Estimating Cost Savings from Early Cancer Diagnosis
title_fullStr Estimating Cost Savings from Early Cancer Diagnosis
title_full_unstemmed Estimating Cost Savings from Early Cancer Diagnosis
title_sort estimating cost savings from early cancer diagnosis
publisher MDPI AG
series Data
issn 2306-5729
publishDate 2017-09-01
description We estimate treatment cost-savings from early cancer diagnosis. For breast, lung, prostate and colorectal cancers and melanoma, which account for more than 50% of new incidences projected in 2017, we combine published cancer treatment cost estimates by stage with incidence rates by stage at diagnosis. We extrapolate to other cancer sites by using estimated national expenditures and incidence rates. A rough estimate for the U.S. national annual treatment cost-savings from early cancer diagnosis is in 11 digits. Using this estimate and cost-neutrality, we also estimate a rough upper bound on the cost of a routine early cancer screening test.
topic cancer
costs
incidence
stage
early diagnosis
treatment
data
url https://www.mdpi.com/2306-5729/2/3/30
work_keys_str_mv AT zurakakushadze estimatingcostsavingsfromearlycancerdiagnosis
AT rakeshraghubanshi estimatingcostsavingsfromearlycancerdiagnosis
AT willieyu estimatingcostsavingsfromearlycancerdiagnosis
_version_ 1725868338609913856

Similar Items